Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)

Bio2RDF identifier

NCT02203773

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT02203773

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT02203773

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

100

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT02203773 arm group 50de2a2f4b7d0e0edebae347696452f4 [clinicaltrials_resource:NCT02203773/arm-group/50de2a2f4b7d0e0edebae347696452f4]

NCT02203773 arm group 5c84083287793f25d0361cb84267da57 [clinicaltrials_resource:NCT02203773/arm-group/5c84083287793f25d0361cb84267da57]

NCT02203773 arm group cbef04154fbd7b4d1597ba833f9894a9 [clinicaltrials_resource:NCT02203773/arm-group/cbef04154fbd7b4d1597ba833f9894a9]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:2775b5a5fcab71a5c18ad01a4f2afdd6

brief summary [clinicaltrials_vocabulary:brief-summary]

This is a Phase 1b, ope ...... tion with posaconazole.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Phase 1b Acute Myelogenous Leu ...... e or Azacitidine (Chemo Combo)

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:00434c1c44841738b7e669d1998c89dc]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:06b779622bc2f669878726d8bcd1603d]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:23b70aec15a05e2ff05e40f955971a7d]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:2ab5a2299a0c475d98cd5c1a0af6456a]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:8f62b5347e84251e265608dcdcace614]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:aa8cc71efa1e007dd01889b447cba656]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:d5540cd9dd86c17a1966216553a8819f]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:d653c311dda6ca83cee3ba85b99cc82b]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:0b3df43592d9c7d37fb74a9fef5cc90f]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:1e15f430d5734d13e7e73559777e5863]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:221a601f6249dd93acb5b1bada50b848]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:3e0dbc0f1e7cb5e71cfc26f791efd3b3]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:8fec76fc1f030a52b0740ba0ad792a32]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:933fc13cdc7faec42f8ec7fa2f754a0a]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:b2bf508f882cd1e43f0b4a471c382f08]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:b88aa34e644d382006506833db79aa26]

Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:e4d031a9ab71270de96e99f465e0757c]

collaborator [clinicaltrials_vocabulary:collaborator]

AbbVie [clinicaltrials_resource:665d7d8b26be61d84f23b5abd7000da9]

completion date [clinicaltrials_vocabulary:completion-date]

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT02203773 [clinicaltrials_resource:b1b26e9adf962f7eb859742c00e6baa7]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2014-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Decitabine [clinicaltrials_resource:18bfe52827074ee1de9677a5187cc486]

Posaconazole [clinicaltrials_resource:9dc8e110392434be5991f63a788c0322]

ABT-199 [clinicaltrials_resource:b0d3e94fa123ccfbfc616580bbb1613e]

Azacitidine [clinicaltrials_resource:d81616fae44f6e2b17296e2e85174395]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Decitabine [clinicaltrials_resource:1290239b74bf72b7aef921f67bdca29d]

Posaconazole [clinicaltrials_resource:7bc2431b70805e539ed41e0fc0f73551]

Azacitidine [clinicaltrials_resource:bef9cccb27cb4e162a278eb0db9fdc5f]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

ABT-199

http://www.w3.org/2001/XMLSchema#string

AML

http://www.w3.org/2001/XMLSchema#string

Acute Myelogenous Leukemia

http://www.w3.org/2001/XMLSchema#string

GDC-0199

http://www.w3.org/2001/XMLSchema#string

Myelogenous Leukemia

http://www.w3.org/2001/XMLSchema#string

Treatment Naive AML

http://www.w3.org/2001/XMLSchema#string

Untreated AML

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

AbbVie [clinicaltrials_resource:665d7d8b26be61d84f23b5abd7000da9]

location [clinicaltrials_vocabulary:location]

Site Reference ID/Investigator# 129718 [clinicaltrials_resource:427dcc18400929bb1a4049d6312682dc]

nct id [clinicaltrials_vocabulary:nct-id]

NCT02203773

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

3

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase 1b Study of ABT-199 (G ...... for Standard Induction Therapy

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

M14-358

http://www.w3.org/2001/XMLSchema#string

overall contact [clinicaltrials_vocabulary:overall-contact]

Jalaja Potluri, MD [clinicaltrials_resource:3ad92ac4ce2c1375bcd65590a8dfc4b7]

overall contact backup [clinicaltrials_vocabulary:overall-contact-backup]

Jalaja Potluri, MD [clinicaltrials_resource:7cf1768fbb7a326a8bc15b5eb1f75bf7]

overall official [clinicaltrials_vocabulary:overall-official]

Jalaja Potluri, MD [clinicaltrials_resource:29600f0e949430253cad193c98294668]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

France: Agence Nationale de Sécurité du Médicament et des produits de santé [clinicaltrials_resource:98fdf270abec09787a15cc9a90566179]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

2014-000687-18

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

AbbVie [clinicaltrials_resource:665d7d8b26be61d84f23b5abd7000da9]

start date [clinicaltrials_vocabulary:start-date]

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT02203773 study design [clinicaltrials_resource:34550e67038cb47c1d5e85bcc5b94ee9]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT02203773

verification date [clinicaltrials_vocabulary:verification-date]

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT02203773

http://www.w3.org/2001/XMLSchema#string

title

Phase 1b Acute Myelogenous Leu ...... e or Azacitidine (Chemo Combo)

@en